Compare JOUT & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOUT | VOGX |
|---|---|---|
| Founded | 1970 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.3M | 482.8M |
| IPO Year | 1994 | 2026 |
| Metric | JOUT | VOGX |
|---|---|---|
| Price | $44.77 | $26.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.4K | ★ 125.1K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $592,415,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.65 | $14.80 |
| 52 Week High | $53.54 | $38.41 |
| Indicator | JOUT | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 53.92 |
| Support Level | $43.02 | N/A |
| Resistance Level | $48.01 | $36.17 |
| Average True Range (ATR) | 1.32 | 3.42 |
| MACD | -0.01 | -1.17 |
| Stochastic Oscillator | 11.48 | 19.52 |
Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.